Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Christopher G Kanakry, M.D.

National Cancer Institute (NCI)

Intervention

First Allogeneic Bone Marrow Transplant (BMT)(procedure)

Enrollment

76 enrolled

Eligibility

4-55 years · All sexes

Timeline

2011 – 2020

Study locations (3)

• Childrens National Medical Center, Washington D.C., District of Columbia, United States
• National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
• University of Oklahoma, Oklahoma City, Oklahoma, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06630221
  Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
  Abhay Singh, MD MPH
• RECRUITINGPHASE1, PHASE2NCT06548230
  A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
  M.D. Anderson Cancer Center
• RECRUITINGPHASE2NCT06802315
  Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
  University of Illinois at Chicago
• ACTIVE NOT RECRUITINGPHASE2NCT07052006
  A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
  Halia Therapeutics, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT05201066
  Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
  Novartis Pharmaceuticals
• RECRUITINGNANCT06886425
  Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
  Assistance Publique Hopitaux De Marseille
• ACTIVE NOT RECRUITINGPHASE3NCT04401748
  Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
  AbbVie
• ACTIVE NOT RECRUITINGPHASE2NCT02912208
  Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
  Associazione Qol-one

See all trials for Myelodysplastic syndrome →